Neurocrine Biosciences, Inc. (NBIX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $130.81. It has a SharesGrow Score of 88/100, indicating a strong investment profile with 7 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of NBIX = $320.39 (+144.9% from the current price, the stock appears undervalued). Analyst consensus target is NBIX = $174 (+32.8% upside).
Valuation: NBIX trades at a trailing Price-to-Earnings (P/E) of 27.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.43.
Financials: revenue is $2.9B, +24.3%/yr average growth. Net income is $479M, growing at +46.2%/yr. Net profit margin is 16.7% (healthy). Gross margin is 98.2% (-0.2 pp trend).
Balance sheet: total debt is $415M against $3.3B equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 3.39 (strong liquidity). Debt-to-assets is 9%. Total assets: $4.6B.
Analyst outlook: 31 / 36 analysts rate NBIX as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 76/100 (Pass), Growth 100/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 76/100 (Pass), Future 94/100 (Pass), Income 70/100 (Pass).
